DGAP-News
Biotest AG: Annual general meeting approves payout of dividend
DGAP-News: Biotest AG / Key word(s): AGM/EGM
Biotest AG: Annual general meeting approves payout of dividend
12.05.2016 / 17:29
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Biotest AG: Annual general meeting approves payout of dividend
12.05.2016 / 17:29
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
PRESS RELEASE
Biotest AG: Annual general meeting approves payout of dividend
- Dividend payout of EUR 0.02 per ordinary share and EUR 0.04 per
preference share
Dreieich/ Frankfurt a. M., 12 May 2016. At the annual general meeting (AGM)
held on 12 May 2016 in Frankfurt/ Main, shareholders of Biotest AG approved
the payment of a dividend. With 74,4 percent of the ordinary share capital
represented at the meeting, a payment of EUR 0.02 per ordinary share and
EUR 0.04 per preference share was resolved with a high degree of approval.
The overall dividend payment will amount to EUR 1.2 million.
The annual general meeting, with 257 shareholders present, formally
discharged the members of the Management Board and Supervisory Board for
financial year 2015.
The full text of the speech given by the CEO of Biotest AG, Dr. Bernhard
Ehmer, at the AGM is available at: http://www.biotest.com/de/en/
investor_relations/shareholders_meeting.cfm
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value
added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialised primarily in the areas of clinical
immunology, haematology and intensive medicine. Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In addition Biotest develops monoclonal antibodies in the
indications of cancer of plasma cells and systemic lupus erythematosus
which are produced by recombinant technologies. Biotest has more than 2,300
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor_relations@biotest.de
PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.de
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
Munich, Stuttgart
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
---------------------------------------------------------------------------
12.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg,
Stuttgart
End of News DGAP News Service
---------------------------------------------------------------------------
463345 12.05.2016
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte